Overview of Clopress

Quick Facts

Property	Description
Active ingredient	Clomipramine (as Hydrochloride)
Form	Capsule or Tablet (Oral)
Pharmacological class	Tricyclic Antidepressant (TCA)
Common use	Modulation of mood and thought patterns
Origin	Synthetic, dibenzazepine-derivative

What Type of Medication is Clopress?

Clopress is a trade name for a prescription medication defined by its active substance, Clomipramine, which is pharmacologically classified as a Tricyclic Antidepressant (TCA). This medication is a synthetic compound derived from the dibenzazepine chemical structure. Clomipramine belongs to the tertiary amine subclass of TCAs, a specific group of psychoactive agents used to regulate central nervous system signaling. This compound is characterized by its potent effects on specific neurotransmitter systems.

Composition and Form of Clomipramine

The active component in this drug is typically incorporated as Clomipramine Hydrochloride (Clomipramine Hcl), which is the chemically stable salt form of the Clomipramine base. The final pharmaceutical product is a single-ingredient product intended exclusively for oral administration and is supplied in solid dosage form, predominantly as a capsule or tablet. Clomipramine is a well-established substance, with Anafranil being another widely recognized brand containing the same formulation, relying solely on the action of the TCA itself.

General Purpose and Action Profile

The general therapeutic purpose of this medication is to provide pharmacological support for stabilizing mood and regulating emotional disturbances. Clomipramine achieves this by functioning as a monoamine reuptake inhibitor, temporarily increasing the availability of key chemical messengers, primarily serotonin and, secondarily, norepinephrine, in the brain's synapses. This action facilitates the regulation of mood and thought patterns. This sustained modulation supports the brain's ability to maintain a balanced level of these substances, which is utilized in addressing complex mental health issues such as persistent, intrusive thought cycles.

Regulatory References

What side effects are possible with Clopress?

Clopress (Clopidogrel) is an antiplatelet medication that carries a primary safety risk of bleeding (hemorrhage) due to its mechanism of action.

Serious and Clinically Significant Adverse Reactions

Adverse reactions associated with Clopress can be categorized by system-organ class, predominantly involving blood and lymphatic disorders and vascular disorders. Bleeding, including life-threatening and fatal bleeding events (such as intracranial and gastrointestinal hemorrhage), is the most commonly reported serious adverse reaction. Patients should be monitored carefully for any signs of bleeding, particularly during the initial weeks of treatment or following invasive procedures.

Very rarely reported, but clinically significant, is Thrombotic Thrombocytopenic Purpura (TTP), a potentially fatal condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, neurological findings, renal dysfunction, and fever. TTP requires urgent treatment, including plasmapheresis.

Common and Other Adverse Reactions

Common adverse reactions typically include bleeding events such as bruising/hematoma, epistaxis (nosebleed), and gastrointestinal bleeding. Other reactions may involve hypersensitivity events like rash or pruritus.

Safety Restrictions and Population Considerations

Contraindications: Clopress is strictly contraindicated in patients with active pathological bleeding (e.g., peptic ulcer or intracranial hemorrhage) and severe hepatic impairment.
Use with Caution: Caution is advised in patients with underlying lesions prone to bleeding, those with renal impairment, or moderate hepatic impairment. The drug is generally not recommended within the first seven days following an acute ischemic stroke.
Surgery: If surgery is planned and an antiplatelet effect is temporarily undesirable, Clopress should be discontinued at a defined time interval before the procedure (e.g., 5 to 7 days, as guided by the physician). The concomitant use of certain other medicines that increase bleeding risk, such as Warfarin and non-steroidal anti-inflammatory drugs (NSAIDs), requires careful clinical consideration.

Overdose and Emergency Response

Overdosage with Clopress (Clomipramine) is officially documented by regulatory authorities as a severe, potentially life-threatening event that necessitates immediate medical intervention. Deaths have been reported following overdosage with this class of medication.

Documented Overdose Manifestations

Critical signs of overdose primarily affect the cardiovascular and central nervous systems. Cardiovascular manifestations documented in the official labeling include severe cardiac dysrhythmias, hypotension, and changes in the electrocardiogram (ECG), such as QRS axis or width abnormalities, which are clinically significant indicators of toxicity. Central Nervous System (CNS) effects include convulsions (seizures), CNS depression leading to coma or stupor, delirium, ataxia, muscle rigidity, and hyperactive reflexes. Other documented signs include tachycardia and severe perspiration.

When to Seek Urgent Help

In any case of known or suspected overdose, seek immediate medical attention. If the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened, call emergency services immediately. The FDA prescribing information recommends contacting a poison control center for current treatment information. Hospital monitoring is required as soon as possible due to the risk of rapid development and potential delayed onset of severe toxicity. Management is designated as symptomatic and supportive; no specific antidote is mentioned in official labeling.

Therapeutic Uses of Clopress

What Clopress Treats: Main Uses and Benefits

The primary therapeutic use of this medication is applied across domains where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations and functional strain. It is commonly used to help with managing conditions such as Major Depressive Disorder, Obsessive-Compulsive Syndromes, Phobias, and Panic Attacks. This application targets conditions where symptoms may intensify temporarily or create noticeable functional strain.

Quick Fact: Therapeutic Use in Obsessive and Compulsive Symptoms

The medication helps address symptom clusters related to recurrent, unwanted thoughts and associated ritualistic behaviors. It is relevant for easing anti-obsessional symptom clusters and supports general well-being during symptomatic phases.

“In specialized clinical contexts, it may be part of symptomatic management in addressing symptoms related to physical discomfort.”

The overall benefit is providing support that helps ease the overall symptom burden in situations involving heightened discomfort. This provides supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.

Regulatory References

New Zealand Medsafe Data Sheet

Eligibility and Restrictions for Use

Eligibility for Clopress (Clomipramine)

Official regulatory documents define strict population eligibility criteria for Clopress (Clomipramine) based on age, concurrent medication use, and existing health conditions.

Absolute Contraindications (Must Not Use)

Clopress is contraindicated and must not be used in several defined patient populations:

Patients with a known hypersensitivity to Clomipramine or any other tricyclic antidepressants (TCAs).
Patients who are concurrently using, or have recently used (within 14 days), a Monoamine Oxidase Inhibitor (MAOI), including linezolid.
Individuals in the acute recovery period following a myocardial infarction (recent heart attack).

Age and Organ Function Restrictions

Population Group	Regulatory Eligibility Status
Pediatric Patients	Use not established for children younger than 10 years of age for any indication. Approved only for Obsessive-Compulsive Disorder (OCD) in children 10 and older (US FDA labeled indication).
Pregnancy/Lactation	Not recommended during pregnancy (FDA Category C) or lactation due to potential risks and excretion into breast milk.
Hepatic/Renal Impairment	Severe hepatic disease is a contraindication in some international labels; caution is warranted in patients with severe renal impairment.

Comorbidity Limitations

Use requires caution in patients with conditions sensitive to anticholinergic effects, such as a history of angle-closure glaucoma, urinary retention, or chronic constipation. Caution is also required in patients with tumors of the adrenal medulla.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Clopress (Clomipramine) is defined by pharmacokinetic and pharmacodynamic restrictions documented in regulatory labeling. The co-administration of certain substances is strictly contraindicated due to the risk of severe outcomes, which is classified across multiple drug categories.

Documented Interaction Restrictions

Classification	Interacting Agents	Required Action/Outcome
Contraindicated Combinations	Monoamine Oxidase Inhibitors (MAOIs), Thioridazine, Pimozide, and QTc-prolonging agents.	Prohibited co-administration due to Serotonin Syndrome or QTc prolongation risk.
Metabolic Inhibition	Potent CYP2D6 inhibitors (e.g., Fluoxetine, Cimetidine, Haloperidol).	Can increase Clomipramine plasma concentration, requiring careful monitoring.
Pharmacodynamic Effects	Other serotonergic drugs (e.g., Triptans, Lithium, St. John’s Wort) and CNS depressants (e.g., Alcohol).	Increased risk of Serotonin Syndrome or additive CNS side effects.

Mandatory Timing Rules

Specific washout periods are required when switching between therapies. Clomipramine must be separated from MAOIs by at least 14 days. When discontinuing Fluoxetine, a separation of at least 5 weeks is required before starting Clopress, due to the long half-life of Fluoxetine’s active metabolite.

Exposure Modification

Co-administration has been documented to increase the plasma levels of other specific drugs, such as phenobarbital and highly protein-bound agents like warfarin. Furthermore, individuals classified as CYP2D6 Poor Metabolizers are officially noted to be at a higher risk of elevated Clomipramine exposure when taking CYP2D6-inhibiting drugs.

Mechanism of Action

Dual Monoamine Neurotransmitter Interaction

The core mechanism involves the inhibition of the Serotonin (5- HT) and Norepinephrine ( NE) Transporters (SERT and NET). The parent molecule and its active metabolite block the reuptake of these chemical messengers, resulting in sustained, higher concentrations in the synaptic cleft. This chronic enhancement triggers a cascade of adaptive changes in neural receptor dynamics within circuits responsible for central signaling, initiating long-term adjustments in the physiological baseline.

Non-Selective Autonomic and Histaminergic Receptor Antagonism

Beyond the monoamine systems, the molecule acts as a non-specific antagonist at several off-target receptors, notably Histamine ( H1) and Muscarinic Cholinergic receptors. This antagonistic action modulates pathways that influence central arousal and peripheral autonomic tone. These parallel mechanisms cause secondary alterations in central arousal and smooth muscle tone, shaping the molecule's complete physiological footprint.

Membrane Stabilization in Nociceptive Pathways

A third component of the mechanism is the blockade of voltage-gated sodium channels ( Na^+). This interaction stabilizes the membranes of specific nerve cells, reducing their electrical excitability and slowing the propagation of nerve impulses. This action reduces neuronal excitability, particularly in circuits that handle sustained or high-frequency neural input.

Dosage and Administration Information

How to Use Clopress: Official Administration Guidelines

Clopress, which contains Clomipramine, is used according to established protocols. This section describes the high-level procedures for its administration, focusing strictly on route, dosage, timing, and patient-specific rules.

Administration Scope

Instruction Entity	Detail
Route of administration	Oral (by mouth), typically as a capsule or tablet.
Dosing schedule	Treatment begins with a low initial dose (e.g., 10 mg or 25 mg daily) and is gradually increased (titrated) over weeks. The recommended adult maximum daily limit is generally 250 mg.
Timing in relation to meals	Doses may be taken with food during the initial phase to mitigate potential gastrointestinal discomfort.
Age-group administration rules	Older Adults (Geriatric) should be started on a lower initial dose (e.g., 10 mg daily) and monitored closely. Pediatric dosing (for children 10 years and older with Obsessive-Compulsive Disorder) is calculated based on body weight or an absolute maximum, whichever is lower.
Missed-dose rules	If a dose is missed, it should be taken when remembered, unless the next dose is imminent. Double doses are not recommended to compensate for a missed dose.
Special procedural conditions	The full stable daily dose is often administered once daily at bedtime to consolidate the dosing schedule. Capsules may be opened and mixed with soft food if swallowing is difficult.

Use Protocol Structure

The standard protocol involves a titration phase—starting at the minimum required amount and slowly increasing—to establish the personalized effective dose, which may take several weeks. Once established, the dose is generally taken as a single administration at night. The use is structured for long-term continuation with a requirement for periodic re-evaluation. Furthermore, the final stage of treatment requires a gradual reduction (tapering) of the dose before the medicine is discontinued.

Recent Clinical Evidence

Clopress: Recent Clinical Evidence

Evidence for Use in Obsessive-Compulsive Disorder (OCD)

Research exploring how symptoms change over time in Obsessive-Compulsive Disorder (OCD) has primarily utilized Randomized Controlled Trials (RCTs). These studies were used to evaluate Clopress against either an inactive substance or other active treatments. The core focus was measuring changes in the severity of obsessions and compulsions using standardized clinical instruments. Studies included both adult populations and specific research examined symptom intensity or variability in children and adolescents aged 10 and older. Findings from some trials described patterns where continued monitoring of patients occurred to assess the patterns of symptom recurrence (relapse) over defined time intervals. Long-term outcomes are not fully established, particularly regarding the patterns observed after the initial measured period beyond the acute phase.

Evidence for Use in Major Depressive Disorder (MDD)

The evidence for MDD was evaluated in studies exploring short-term symptom changes. Research examined outcomes related to functional imbalance by measuring changes in depressive symptoms using global clinician ratings and specific clinical scales. Studies reported how symptoms evolved, noting measurements related to the time required to see a pattern of clinical response. Controlled long-term follow-up durations were limited, with most extended data coming from open-label studies. Data for certain groups, such as contemporary, large-scale studies on its use as a first-line therapy, remain insufficient.

Evidence for Use in Panic Disorder

Clopress was studied for Panic Disorder, a condition characterized by fluctuating manifestations. The research primarily utilized Randomized Controlled Trials comparing the drug against placebo. Studies evaluated the frequency and severity of panic attacks, along with measuring overall functional imbalance. Findings describe patterns observed in the studies, reporting varying measurements in the changes in panic attack occurrences over an acute period. Clinical guidance bodies suggest its placement as a non-first-line option, indicating that the overall evidence profile has certain constraints regarding its typical placement in treatment protocols.

Key Research Gaps and Areas of Uncertainty

Research has explored what evidence is available beyond the acute treatment phase. Studies examined symptom intensity or variability over defined time intervals to assess the patterns observed after the initial measured period. Studies report mixed or inconsistent findings regarding whether a higher study concentrations corresponds predictably to measured changes in symptom scores in some contexts. Data for long-term outcomes are still emerging, and the long-term effects are not fully established across all indications.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Clopress (FAQ)

Q: Does Clopress have a generic version available?

A: Yes, the active ingredient, Clomipramine Hydrochloride, is available as a generic drug. Official resources confirm the generic medication is available under that name.

Q: Is Clopress the same as aspirin or other blood thinners?

A: No, according to the official product information, Clomipramine is classified as a tricyclic antidepressant (TCA). It works by affecting neurotransmitter activity in the brain, which is a different mechanism than how antiplatelet or anticoagulant medicines (blood thinners) function.

Q: How does the mechanism of Clopress differ from traditional blood thinners?

A: The mechanism of Clopress is defined by regulatory documents as acting as a monoamine reuptake inhibitor in the central nervous system. This differs significantly from traditional blood thinners, which work to prevent blood clots. The official classification is as a tricyclic antidepressant.

Q: Is Clopress considered a P2Y12 inhibitor?

A: No, the official documents classify Clopress (Clomipramine) as a tricyclic antidepressant (TCA). It is not classified as a P2Y12 inhibitor, which is a specific class of antiplatelet medicines.

Q: Is there a boxed warning associated with Clopress, and what does it cover?

A: Yes, the FDA regulatory label includes a Boxed Warning. This warning specifically addresses the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults.

Q: How quickly does Clopress start working to prevent problems?

A: Symptom improvement may not occur immediately, as the effect is not acute. Studies and official information indicate that it may take two to three weeks or more to notice a pattern of clinical response. Clinical response often requires a stable dose to be established.

Q: What is the average time a person needs to take Clopress?

A: According to the official product information, treatment is typically structured for long-term continuation after the initial response is achieved. Maintenance therapy is continued to avoid relapse, and the duration of this treatment is reviewed periodically, as noted in product information.

Q: What are the known risks of suddenly stopping Clopress?

A: Abrupt discontinuation should be avoided because it may cause withdrawal symptoms such as dizziness, headache, nausea, or irritability. A gradual dose reduction (tapering) is necessary before the medicine is discontinued.

Q: What are the most common side effects people report when starting Clopress?

A: Official regulatory documents list several commonly reported adverse effects, including dry mouth, constipation, nausea, drowsiness, dizziness, and tremor. Increased appetite and sexual dysfunction are also among the commonly reported effects.

Q: Can taking Clopress cause excessive tiredness or fatigue?

A: Yes, official drug information indicates that drowsiness and fatigue have been reported as common adverse effects.

Q: Does Clopress cause weight gain or weight loss?

A: Yes, official regulatory labeling reports that increased appetite and weight gain have been observed as common adverse effects.

Q: Will the side effects of Clopress go away on their own over time?

A: Official information suggests that if mild, common side effects are experienced, they may lessen or resolve within a few days or a couple of weeks as the body adjusts to the medicine.

Q: What signs of bleeding should prompt a person to seek immediate medical attention?

A: Regulatory documents note signs of blood disorders that warrant evaluation, which may include easy bruising or bleeding, paleness, or unusual weakness. Immediate medical attention is necessary if severe symptoms occur.

Q: Is a person on Clopress at increased risk for vision problems?

A: Blurred vision is a common side effect reported in official documents. Severe symptoms like eye pain or seeing halos around lights can be signs of a serious condition, such as angle-closure glaucoma, and require prompt medical evaluation.

Q: Can Clopress interact with common over-the-counter pain relievers like ibuprofen or naproxen?

A: Official documents advise caution regarding co-administration with Non-Steroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen. This is because combining these may increase the risk of bleeding.

Q: Can Clopress be taken with a morning cup of coffee or other caffeine products?

A: Regulatory information advises caution regarding the use of caffeine-containing products. This is due to reports that the medicine may reduce the metabolism of caffeine in the body.

Q: Does Clopress interact with common blood pressure or cholesterol medicines?

A: Regulatory documents indicate that Clopress may prevent the intended therapeutic response to certain antihypertensives (blood pressure medicines). Caution is also advised when using it with other medicines that may affect the heart’s electrical rhythm.

Q: How long does Clopress stay in the system after the last tablet is taken?

A: According to regulatory pharmacokinetics data, the medicine is eliminated from the body slowly. The elimination half-life of clomipramine is generally reported to be in the range of 19 to 37 hours.

Q: Can Clopress be used by people with a history of stomach ulcers?

A: Official warnings advise caution in patients with a history of cardiovascular or cerebrovascular disease. The drug is associated with gastrointestinal complaints and an increased bleeding risk, which necessitates careful consideration for individuals with relevant past conditions.

Q: Is Clopress safe for use in older adults (e.g., those over 65)?

A: Regulatory labeling explicitly recommends that dosing be cautious and typically started at the lower end of the dose range for older adults. This caution is based on potential changes in organ function and the increased risk of hyponatremia in this population.

Q: Is it necessary to inform a dentist or surgeon that I am taking Clopress?

A: Official product information states that health professionals should be informed before any surgery, dental treatment, or emergency treatment. This is because combining the medicine with agents used during surgery may increase the risk of side effects.

Q: Can Clopress cause long-term side effects that appear years later?

A: Official documents advise that periodic monitoring of cardiac and hepatic (liver) function is recommended during long-term therapy. The long-term usefulness of the drug should also be periodically reevaluated for extended treatment periods, as noted in official documents.

Q: How does Clopress affect the risk of stroke compared to heart attack?

A: The official label indicates that the drug may cause fluctuations in blood pressure. It should be used with caution in patients with a history of cardiovascular or cerebrovascular disease (like a stroke).

How should Clopress be stored and disposed of?

Clopress (clomipramine hydrochloride) must be stored and handled according to specific regulatory requirements to maintain its stability.

Official Storage Conditions

Requirement	Condition
Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Prohibition	Do not freeze or store above 30 C
Protection	Keep protected from excess moisture and light
Container	Must be stored in a tightly closed, original container
Child Safety	Keep out of the sight and reach of children

Disposal Instructions

Unused or expired Clopress must not be thrown directly into household trash or flushed down the toilet, unless the official labeling directs otherwise. Disposal should primarily be carried out by checking with a pharmacist or local waste disposal company to utilize a drug take-back program. If a program is unavailable, follow specific household disposal guidelines by mixing the medication with an undesirable substance before sealing and discarding.

Clopress